Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.47 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367612 | 0.84 | MKNK1 (0.57) | KDRCNR1MKNK1GSTO1CCNE1 | |
| SCHEMBL5354063 | 0.84 | MKNK1 (0.64) | KDRCNR1MKNK1GSTO1CCNE1 | |
| SCHEMBL5357836 | 0.83 | KDR (0.52) | KDRCNR1MKNK1GSTO1CCNE1 | |
| SCHEMBL5356934 | 0.81 | KDR (0.50) | KDRCNR1MKNK1GSTO1CHEK1 | |
| SCHEMBL5359220 | 0.81 | MKNK1 (0.57) | KDRCNR1MKNK1GSTO1CCNE1 | |
| SCHEMBL5353583 | 0.80 | MKNK1 (0.55) | KDRCNR1MKNK1GSTO1CCNE1 | |
| SCHEMBL5354171 | 0.80 | MKNK1 (0.55) | KDRCNR1MKNK1GSTO1CCNE1 | |
| SCHEMBL5353588 | 0.80 | MKNK1 (0.55) | KDRCNR1MKNK1GSTO1CCNE1 | |
| SCHEMBL14408030 | 0.79 | CNR2 (0.62) | KDRCNR1MKNK1GSTO1CHEK1 | |
| SCHEMBL5349672 | 0.79 | KDR (0.47) | KDRCNR1MKNK1GSTO1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20040192926-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192926-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CNR1 3794/4885MKNK1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.